May 17, 2023
|
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
|
May 15, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
May 9, 2023
|
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
|
May 3, 2023
|
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
|
May 1, 2023
|
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
|
Apr 26, 2023
|
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
|
Apr 18, 2023
|
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
|
Apr 13, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Apr 12, 2023
|
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
|
Mar 2, 2023
|
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
|